Cargando…

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis

AIMS: Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of early-stage ATTR-CM remains poorly characterized. METHODS AND RESULTS: A retrospective mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Law, Steven, Bezard, Melanie, Petrie, Aviva, Chacko, Liza, Cohen, Oliver C, Ravichandran, Sriram, Ogunbiyi, Olabisi, Kharoubi, Mounira, Ganeshananthan, Sashiananthan, Ganeshananthan, Sharmananthan, Gilbertson, Janet A, Rowczenio, Dorota, Wechalekar, Ashutosh, Martinez-Naharro, Ana, Lachmann, Helen J, Whelan, Carol J, Hutt, David F, Hawkins, Philip N, Damy, Thibaud, Fontana, Marianna, Gillmore, Julian D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279112/ https://www.ncbi.nlm.nih.gov/pubmed/35608040 http://dx.doi.org/10.1093/eurheartj/ehac259

Ejemplares similares

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy
por: Law, Steven, et al.
Publicado: (2022)

Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis
por: Bandera, Francesco, et al.
Publicado: (2022)

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022)

Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience
por: Razvi, Yousuf, et al.
Publicado: (2023)

Diagnostic value of fat aspirates for amyloidosis in 950 patients
por: Gilbertson, JA, et al.
Publicado: (2015)

Five novel TTR variants: associated phenotypes and structural consequences
por: Rowczenio, Dorota, et al.
Publicado: (2015)

Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg
por: Broussier, Amaury, et al.
Publicado: (2021)

PW01-021 – The phenotype of FMF due to deletion M694
por: Lachmann, HJ, et al.
Publicado: (2013)

Empirical use of anakinra in AA amyloidosis of uncertain aetiology
por: Lane, T, et al.
Publicado: (2015)

Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild‐type cardiac amyloidosis
por: Kharoubi, Mounira, et al.
Publicado: (2020)

Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022)

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment
por: Oghina, Silvia, et al.
Publicado: (2021)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
por: Ravichandran, Sriram, et al.
Publicado: (2022)

OR14-001 – Tocilizumab in autoinflammation and AA amyloidosis
por: Lane, T, et al.
Publicado: (2013)

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis
por: Quarta, Candida Cristina, et al.
Publicado: (2017)

DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience
por: Hutt, David, et al.
Publicado: (2015)

Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
por: Dungu, Jason, et al.
Publicado: (2012)

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
por: Ravichandran, Sriram, et al.
Publicado: (2021)

Clinical symptoms and molecular investigations in 13 patients with Schnitzler syndrome identified at the single UK centre
por: Rowczenio, D, et al.
Publicado: (2015)

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome
por: Pinney, Jennifer H., et al.
Publicado: (2013)

Deletion in MEFV resulting in the loss of p.M694 residue as the cause of autosomal dominant familial Mediterranean fever in North Western European Caucasians - a case series and genetic exploration
por: Rowczenio, D, et al.
Publicado: (2015)

The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis
por: Cohen, Oliver C., et al.
Publicado: (2020)

Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
por: Martinez-Naharro, Ana, et al.
Publicado: (2022)

(99m)Tc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis
por: Quarta, Candida Cristina, et al.
Publicado: (2021)

Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient
por: McColgan, P., et al.
Publicado: (2014)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

PW02-014 - Long term outcome and quality of life in TRAPS
por: Lane, T, et al.
Publicado: (2013)

Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years
por: Ioannou, Adam, et al.
Publicado: (2022)

Treatment of acquired transthyretin amyloidosis in domino liver transplantation
por: Tsamis, Konstantinos I., et al.
Publicado: (2022)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation
por: Oghina, Silvia, et al.
Publicado: (2021)

Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’
por: Damy, Thibaud, et al.
Publicado: (2021)

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria
por: Sharpley, Faye A., et al.
Publicado: (2020)

Deleterious effect of right ventricular pacing in patients with cardiac transthyretin amyloidosis: potential clinical benefit of cardiac resynchronization therapy
por: Aouate, David, et al.
Publicado: (2020)

Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis
por: Rauf, Muhammad Umaid, et al.
Publicado: (2023)

Transthyretin-related Familial Amyloid Polyneuropathy (TTR-FAP) caused by a very rare, de novo mutation in a Polish patient.
por: Lipowska, Marta, et al.
Publicado: (2015)

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis
por: Rezk, Tamer, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p7jf11qij8ql5inr4sief7a0b7